Unicycive(UNCY)

搜索文档
Unicycive Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 – UNCY
Globenewswire· 2025-10-02 04:17
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025. Follow the link below to get more information and be contacted by a member of our team: ...
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY
Globenewswire· 2025-10-01 05:30
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...
UNICYCIVE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Investors in Unicycive to Contact the Firm Regarding Filed Class Action Lawsuit
Globenewswire· 2025-09-30 05:11
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NE ...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY
Globenewswire· 2025-09-28 01:26
NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY
Businesswire· 2025-09-26 03:19
LOS ANGELES--(BUSINESS WIRE)--Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY. ...
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm
Globenewswire· 2025-09-25 05:03
文章核心观点 - 律师事务所Bragar Eagel & Squire, P.C.宣布,代表在2024年3月29日至2025年6月27日期间购买Unicycive Therapeutics公司证券的投资者,对该公司提起集体诉讼 [8] - 诉讼指控Unicycive公司就其新药申请相关的生产合规准备状态,向投资者做出了虚假和/或误导性陈述,未披露其满足FDA生产合规要求的能力被夸大 [8] - 受FDA审查结果和完全回应函影响,Unicycive公司股价出现两次大幅下跌,累计跌幅显著 [8] 诉讼事件概述 - 集体诉讼已向美国加州北区地方法院提交,投资者申请担任首席原告的截止日期为2025年10月14日 [8] - 诉讼涉及的类别期为2024年3月29日至2025年6月27日 [8] 指控具体内容 - 被告方吹捧了其药物OLC用于治疗透析慢性肾病患者高磷血症的新药申请前景 [8] - 被告方向投资者保证公司已准备好并有能力满足美国FDA的生产合规要求 [8] - 指控称被告方未能披露其满足FDA生产合规要求的能力被夸大 [8] 股价影响事件 - 2025年6月10日,公司公告FDA在其第三方生产供应商处发现cGMP合规缺陷,导致公司股价下跌超过40% [8] - 2025年6月30日,公司公告FDA就OLC新药申请发出完全回应函,再次提及cGMP缺陷,导致公司股价下跌近30%,收盘报每股4.77美元 [8]
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive
Prnewswire· 2025-09-24 23:30
Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional inform ...
Lost Money on Unicycive Therapeutics, Inc.(UNCY)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Prnewswire· 2025-09-22 20:45
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). ...
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Prnewswire· 2025-09-22 16:27
诉讼核心信息 - Schall Law Firm提醒投资者针对Unicycive Therapeutics, Inc (NASDAQ: UNCY) 的集体诉讼已提起 该诉讼指控公司违反了1934年证券交易法的§§10(b)和20(a)条款以及美国证券交易委员会制定的10b-5规则 [1] - 诉讼涉及的集体诉讼期定义为2024年3月29日至2025年6月27日期间购买公司证券的投资者 这些投资者被鼓励在2025年10月14日前联系该律师事务所 [2] 指控内容 - 指控称公司在市场上发布了虚假和误导性声明 夸大了其满足FDA生产合规要求的能力 [4] - 公司被指控夸大了其用于治疗透析慢性肾病患者的血磷过高药物OLC获得FDA批准的可能性 [4] - 基于这些事实 公司在整个集体诉讼期间的公开声明是虚假的且具有重大误导性 当市场了解到Unicycive的真相后 投资者遭受了损失 [4] 律师事务所信息 - Schall Law Firm是一家全国性的股东权利诉讼公司 代表全球投资者 专门从事证券集体诉讼和股东权利诉讼 [5]
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Globenewswire· 2025-09-21 20:16
公司事件 - 律师事务所Faruqi & Faruqi正在调查Unicycive Therapeutics公司 并提醒投资者在2025年10月14日前申请成为集体诉讼的首席原告[4] - 诉讼指控公司及高管违反联邦证券法 通过做出虚假和/或误导性陈述及/或未能披露相关信息[6] - 指控具体内容包括公司夸大其满足FDA生产合规要求的能力 以及夸大OLC新药申请的监管前景[6] 监管进展 - 2025年6月10日公司披露FDA在其第三方制造供应商处发现cGMP合规缺陷 导致无法进行标签讨论[7] - 此消息导致公司股价下跌3.68美元 跌幅达40.89% 收盘价为5.32美元[7] - 2025年6月30日FDA针对OLC新药申请发出完整回复函 再次提及先前发现的cGMP缺陷[8] - 此消息导致公司股价进一步下跌2.03美元 跌幅达29.85% 收盘价为4.77美元[8] 投资者影响 - 诉讼涵盖期间为2024年3月29日至2025年6月27日 针对损失超过50,000美元的投资者[1] - 法院指定的首席原告将是集体成员中财务利益最大且具有代表性的投资者[9] - 投资者可选择通过律师申请成为首席原告 或保持缺席集体成员身份[9]